Biopharma | May 13, 2026
Agilent and Veeda collaborate to strengthen regulatory-ready biopharma analytics
The two companies will establish a joint Center of Excellence (CoE) in Bengaluru
The two companies will establish a joint Center of Excellence (CoE) in Bengaluru
Strong export-led growth and improved profitability as the company focuses on CNS drug development and global regulatory footprint
The once-daily oral therapy is the first and only tyrosine kinase 2 (TYK2) inhibitor approved in the European Union for this indication, marking a significant expansion of its immunology portfolio
U.S. business drives strong growth as Lupin reports 57% rise in Q4 U.S. sales and 43% increase in gross profit
Former DCGI and now advisor to UP CM highlights medical device growth, healthcare expansion, and investment opportunities in the state
As per GlobalData, CARsgen’s satri-cel could mark a major breakthrough in solid tumor treatment as competition intensifies
Fresenius Kabi's approved generic therapy addresses acute symptomatic hypocalcemia and targets a US market valued at nearly $71 million
The conference brought together over 500 doctors and 150 nutritionists to discuss emerging obesity-related challenges
Approval marks the second generic semaglutide clearance in Canada and strengthens OneSource’s position in complex injectable CDMO programs
Under the new policy, financial assistance has been increased to Rs 50 lakh per patient to improve treatment access
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
